By targeting drug-resistant EGFR mutations and leveraging the potential of NGS technologies, we aim to pave the way for more personalized and effective treatments, ultimately improving outcomes and quality of life for those affected by EGFR-driven NSCLC cancers. The gene discussed is EGFR; the disease is cancer.